BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Urological cancer detection and technology innovation: opportuniti
 es and challenges. - Professor Vincent Gnanapragasam\, Professor or Urolog
 y\, University of Cambridge
DTSTART:20220127T160000Z
DTEND:20220127T170000Z
UID:TALK167630@talks.cam.ac.uk
CONTACT:Kirsty Shepherd
DESCRIPTION:Vincent Gnanapragasam is Professor of Urology in the Universit
 y of Cambridge and an Honorary Consultant Urologist at Addenbrooke’s Hos
 pital\, Cambridge. Vincent’s research has covered the full spectrum of b
 asic science\, translational\, clinical and epidemiological disciplines in
  prostate cancer. He has developed and implemented novel prognostic predic
 tion models for both group stratified cohorts Cambridge Prognostic Groups 
 and for individualised prediction Predict Prostate for personalised manage
 ment of prostate cancer. In 2021 the Cambridge Prognostic Groups was offic
 ially adopted by the UK National Institute for Health and Care l Excellenc
 e (NICE) as the new recommended risk stratification tool in the national p
 rostate cancer guidelines (NG131).Predict prostate is the only decision ai
 d endorsed by the UK NICE National Guidelines on prostate cancer. He has a
 lso pioneered risk stratified pathways for active surveillance follow up a
 nd setup one of the first dedicated surveillance clinics for early disease
  monitoring. He has developed and led numerous investigator led multicentr
 e clinical trials including TAPS01\, Predict Prostate RCT\, PRIM biomarker
  study\, and the NIHRi4i funded CAMPROBE study (based on his own invention
  of a new simple device for infection free prostate biopsies). To further 
 interdisciplinary research in prostate cancer he established the Translati
 onal Prostate Cancer Group (TPCG) in Cambridge with colleagues from urolog
 y\, oncology\, radiology\, pathology and basic science. He has also establ
 ished links with STEM scientists to develop biosensors for cancer detectio
 n across different platforms. He is also Chief Investigator of the DIAMOND
  study which hold over 3000 bio-samples\, tissue and annotated clinical da
 ta for biomarker discovery in urological diseases. More recently\, with co
 lleagues from the TPCG\, he has established a platform for integrated geno
 mics and clinical profiling to explore the potential for targeted adjuvant
  therapies to improve primary cure rates in poor prognosis prostate cancer
 . In the University of Cambridge\, he leads the Division of Urology in the
  Department of Surgery and established the Cambridge Urology Translational
  Research and Clinical Trials office which has to date recruited>1600 pati
 ents to various NIHR and portfolio urology trials. He is clinical director
 ate lead for urology research. He holds patents\, editorial positions and 
 has won prizes for research\, including the CE Alken prize\, Urological Re
 search Society Medal and a Hunterian Professorship. In the University of C
 ambridge\, he is a recipient of the Vice-Chancellors Award for Research Im
 pact (Established Researcher). \n
LOCATION:Meeting ID: 819 6343 0914 Passcode: 844817
END:VEVENT
END:VCALENDAR